Evidence map›Paper›PMID 35923561›Full record

ArticleActa naturae

The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.

N S Vasileva, A B Ageenko, V A Richter, E V Kuligina

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

N S VasilevaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, 630090 Russia.
A B AgeenkoInstitute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, 630090 Russia.
V A RichterInstitute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, 630090 Russia.
E V KuliginaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk, 630090 Russia.
Institute of Chemical Biology and Fundamental Medicine · RUSiberian Branch of the Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The resistance of glioblastoma to existing therapies puts limits on quality-of-life improvements and patient survival with a glioblastoma diagnosis. The development of new effective glioblastoma therapies is based on knowledge about the mechanisms governing tumor resistance to therapeutic agents. Virotherapy is one of the most actively developing approaches to the treatment of malignant neoplasms: glioblastoma in particular. Previously, we demonstrated that the recombinant vaccinia virus VV-GMCSF-Lact exhibits

Indexed as

cancer stem cellsglioblastomamechanisms of glioblastoma resistanceoncolytic virusesVV-GMCSF-Lact

Identifiers

PMID35923561
PMCPMC9307987
OpenAlexW4286490903

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.